Download
00392_2023_Article_2317.pdf 2,19MB
WeightNameValue
1000 Titel
  • Safety of dobutamine or adenosine stress cardiac magnetic resonance imaging in patients with left ventricular thrombus
1000 Autor/in
  1. Weberling, Lukas Damian |
  2. Seitz, Sebastian |
  3. Salatzki, Janek |
  4. Ochs, Andreas |
  5. Heins, Jannick |
  6. Haney, Ailís C. |
  7. Siry, Deborah |
  8. Frey, Norbert |
  9. André, Florian |
  10. Steen, Henning |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2023
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-10-16
1000 Erschienen in
1000 Quellenangabe
  • 113(3):446-455
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00392-023-02317-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10881726/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Left ventricular (LV) thrombus formation is a common but potentially serious complication, typically occurring after myocardial infarction. Due to perceived high thromboembolic risk and lack of safety data, stress cardiac magnetic resonance (CMR) imaging especially with dobutamine is usually avoided despite its high diagnostic yield. This study aimed to investigate the characteristics, safety and outcome of patients with LV thrombus undergoing dobutamine or vasodilator stress CMR.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Patients undergoing stress CMR with concomitant LV thrombus were retrospectively included. Risk factors, comorbidities, and previous embolic events were recorded. Periprocedural safety was assessed for up to 48 h following the examination. Major adverse cardiac events (MACE) 12 months before the diagnosis were compared to 12 months after the exam and between patients and a matched control group. Additionally, patients were followed up for all-cause mortality.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>95 patients (78 male, 65 ± 10.7 years) were included. Among them, 43 patients underwent dobutamine (36 high-dose, 7 low-dose) and 52 vasodilator stress CMR. Periprocedural safety was excellent with no adverse events. During a period of 24 months, 27 MACE (14.7%) occurred in patients and controls with no statistical difference between groups. During a median follow-up of 33.7 months (IQR 37.6 months), 6 deaths (6.3%) occurred. Type of stress agent, thrombus mobility, or protrusion were not correlated to embolic events or death.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The addition of a stress test to a CMR exam is safe and does increase the generally high cardioembolic event rate in LV thrombus patients. Therefore, it is useful to support reperfusion decision-making.</jats:p> </jats:sec><jats:sec> <jats:title>Graphical Abstract</jats:title> </jats:sec>
1000 Sacherschließung
lokal Thrombosis/pathology [MeSH]
lokal Vasodilator Agents/adverse effects [MeSH]
lokal Humans [MeSH]
lokal Thrombosis/etiology [MeSH]
lokal Magnetic Resonance Imaging, Cine [MeSH]
lokal Retrospective Studies [MeSH]
lokal Cardiovascular imaging
lokal Dobutamine
lokal CMR
lokal Stroke
lokal Magnetic Resonance Imaging [MeSH]
lokal Adenosine
lokal LV thrombus
lokal Male [MeSH]
lokal Original Paper
lokal Dobutamine/adverse effects [MeSH]
lokal Thrombosis/diagnosis [MeSH]
lokal Adenosine [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-7240-6155|https://frl.publisso.de/adhoc/uri/U2VpdHosIFNlYmFzdGlhbg==|https://frl.publisso.de/adhoc/uri/U2FsYXR6a2ksIEphbmVr|https://frl.publisso.de/adhoc/uri/T2NocywgQW5kcmVhcw==|https://frl.publisso.de/adhoc/uri/SGVpbnMsIEphbm5pY2s=|https://frl.publisso.de/adhoc/uri/SGFuZXksIEFpbMOtcyBDLg==|https://frl.publisso.de/adhoc/uri/U2lyeSwgRGVib3JhaA==|https://frl.publisso.de/adhoc/uri/RnJleSwgTm9yYmVydA==|https://frl.publisso.de/adhoc/uri/QW5kcsOpLCBGbG9yaWFu|https://frl.publisso.de/adhoc/uri/U3RlZW4sIEhlbm5pbmc=
1000 Hinweis
  • DeepGreen-ID: 7a142d9a49e94fdeb8e5c6eb953eac0a ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Deutsches Zentrum für Herz-Kreislaufforschung |
  2. Universitätsklinikum Heidelberg |
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Deutsches Zentrum für Herz-Kreislaufforschung |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Heidelberg |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6495760.rdf
1000 Erstellt am 2025-02-04T10:54:06.553+0100
1000 Erstellt von 322
1000 beschreibt frl:6495760
1000 Zuletzt bearbeitet 2025-09-14T02:03:56.186+0200
1000 Objekt bearb. Sun Sep 14 02:03:56 CEST 2025
1000 Vgl. frl:6495760
1000 Oai Id
  1. oai:frl.publisso.de:frl:6495760 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source